摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

geneticin | 49863-47-0

中文名称
——
中文别名
——
英文名称
geneticin
英文别名
G418;gentamicin G418;(1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranoside;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(1-hydroxyethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
geneticin化学式
CAS
49863-47-0
化学式
C20H40N4O10
mdl
——
分子量
496.558
InChiKey
BRZYSWJRSDMWLG-CAXSIQPQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >193°C (dec.)
  • 沸点:
    760.3±60.0 °C(Predicted)
  • 密度:
    1.47±0.1 g/cm3(Predicted)
  • 溶解度:
    H2O:50 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    -5.8
  • 重原子数:
    34
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    248
  • 氢给体数:
    10
  • 氢受体数:
    14

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S22,S24/25
  • 危险类别码:
    R20/21/22
  • WGK Germany:
    3

反应信息

  • 作为反应物:
    描述:
    geneticin 在 C6 dehydrogenase AprQ 作用下, 以 aq. buffer 为溶剂, 反应 1.0h, 生成 6'-dehydro-6'-oxo-G418
    参考文献:
    名称:
    C3 脱氧途径的表征揭示了氨基糖苷类生物合成的关键分支点
    摘要:
    安普霉素是一种临床上有趣的氨基糖苷类抗生素 (AGA),它含有一个非常独特的双环八糖部分,并且这种八糖在 C3 位置被脱氧。尽管大多数含 2-脱氧链霉胺的 AGA 的生物合成途径已得到充分表征,但安普霉素生物合成途径(包括 C3 脱氧过程)长期以来一直未知。在这里,我们报告了通过一系列遗传、生化和生物信息学研究对安普霉素生物合成的详细调查。我们表明 AprD4 是一种新型自由基 S-腺苷-l-甲硫氨酸 (SAM) 酶,它使用非规范的 CX3CX3C 基序结合 [4Fe-4S] 簇,并催化巴马明的脱水,巴马明是安普霉素生物合成中的一种假双糖中间体。我们还表明 AprD3 是一种 NADPH 依赖性还原酶,可催化 AprD4 催化反应中脱水产物的还原,生成 lividamine,一种 C3' 脱氧的 paromamine 产物。AprD4 和 AprD3 不形成紧密的催化复合物,如蛋白质复合物
    DOI:
    10.1021/jacs.6b02221
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
    申请人:MERCK & CO INC
    公开号:WO2009152025A1
    公开(公告)日:2009-12-17
    The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
    本发明涉及某些咪唑衍生物,其可用作脂肪酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
  • [EN] PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES COMME INHIBITEURS DE FAAH
    申请人:MERCK & CO INC
    公开号:WO2009151991A1
    公开(公告)日:2009-12-17
    The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease
    本发明涉及某些咪唑衍生物,其可用作脂肪酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
  • [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
    申请人:REMYND NV
    公开号:WO2016083490A1
    公开(公告)日:2016-06-02
    This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物,其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物,更具体地用于预防或治疗与淀粉样蛋白相关的疾病,更具体地说是某些神经系统疾病,如被统称为tau病变的疾病,以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。
  • [EN] SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION<br/>[FR] COMPOSÉS DE BENZYLAMINE SUBSTITUÉS, LEUR UTILISATION EN MÉDECINE, EN PARTICULIER DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE C (VHC)
    申请人:ASTEX THERAPEUTICS LTD
    公开号:WO2013064538A1
    公开(公告)日:2013-05-10
    The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is selected from hydrogen and a group R2a; R2a is selected from an optionally substituted acyclic d-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R1 and R2 is other than hydrogen; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S; R4a is selected from halogen; cyano; C1-4 alkyl optionally substituted with one or more fluorine atoms; C1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C1-4 alkyl; and C1-2 alkoxy-C1-4 alkyl; R5 is selected from hydrogen and a substituent R5a; and R5a is selected from C1-2 alkyl optionally substituted with one or more fluorine atoms; C1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino, The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.
    该发明提供了以下式(I)的化合物,或其盐、N-氧化物或互变异构体,其中A为CH、CF或氮;E为CH、CF或氮;R0为氢或C1-2烷基;R1a选自CONH2;CO2H;一个可选择取代的非环状C1-8碳氢化合物基团;以及一个可选择取代的含有3至7个环成员的单环碳环或杂环基团,其中0、1、2、3或4个是从O、N和S中选择的杂原子环成员;R2选自氢和一个基团R2a;R2a选自一个可选择取代的非环状d-8碳氢化合物基团;一个可选择取代的含有3至7个环成员的单环碳环或杂环基团,其中0、1或2个环成员是从O、N和S中选择的杂原子环成员;以及一个可选择取代的含有9或10个环成员的双环杂环基团,其中1或2个环成员是氮原子;其中R1和R2中至少一个不是氢;R3选自一个可选择取代的含有0、1、2或3个从N、O和S中选择的杂原子环成员的3至10个成员的单环或双环碳环或杂环环;R4a选自卤素;氰基;C1-4烷基,可选择取代一个或多个氟原子;C1-4烷氧基,可选择取代一个或多个氟原子;羟基-C1-4烷基;和C1-2烷氧基-C1-4烷基;R5选自氢和一个取代基R5a;R5a选自C1-2烷基,可选择取代一个或多个氟原子;C1-3烷氧基,可选择取代一个或多个氟原子;卤素;环丙基;氰基;和氨基。这些化合物对丙型肝炎病毒具有活性,并可用于预防或治疗丙型肝炎病毒感染。
  • [EN] OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS D'OXAZOLE UTILES COMME INHIBITEURS DE FAAH
    申请人:MERCK & CO INC
    公开号:WO2010017079A1
    公开(公告)日:2010-02-11
    The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
    本发明涉及某些噁唑衍生物,其可用作脂肪酸酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
查看更多